Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy
Abstract Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. T...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85339-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544818434506752 |
|---|---|
| author | Shigeo Ohba Takao Teranishi Kazuyasu Matsumura Masanobu Kumon Daijiro Kojima Eiji Fujiwara Kazutaka Nakao Kiyonori Kuwahara Kazuhiro Murayama Eriel Sandika Pareira Seiji Yamada Masahiro Joko Shunsuke Nakae Jun Muto Yuya Nishiyama Kazuhide Adachi Hikaru Sasaki Masato Abe Mitsuhiro Hasegawa Yuichi Hirose |
| author_facet | Shigeo Ohba Takao Teranishi Kazuyasu Matsumura Masanobu Kumon Daijiro Kojima Eiji Fujiwara Kazutaka Nakao Kiyonori Kuwahara Kazuhiro Murayama Eriel Sandika Pareira Seiji Yamada Masahiro Joko Shunsuke Nakae Jun Muto Yuya Nishiyama Kazuhide Adachi Hikaru Sasaki Masato Abe Mitsuhiro Hasegawa Yuichi Hirose |
| author_sort | Shigeo Ohba |
| collection | DOAJ |
| description | Abstract Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%. |
| format | Article |
| id | doaj-art-61f5d0ce26074aa9a7f6b65752b7bd77 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-61f5d0ce26074aa9a7f6b65752b7bd772025-01-12T12:17:00ZengNature PortfolioScientific Reports2045-23222025-01-011511910.1038/s41598-025-85339-xFactors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapyShigeo Ohba0Takao Teranishi1Kazuyasu Matsumura2Masanobu Kumon3Daijiro Kojima4Eiji Fujiwara5Kazutaka Nakao6Kiyonori Kuwahara7Kazuhiro Murayama8Eriel Sandika Pareira9Seiji Yamada10Masahiro Joko11Shunsuke Nakae12Jun Muto13Yuya Nishiyama14Kazuhide Adachi15Hikaru Sasaki16Masato Abe17Mitsuhiro Hasegawa18Yuichi Hirose19Department of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Radiology, Fujita Health University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Diagnostic Pathology, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Tokyo Dental College Ichikawa General HospitalDepartment of Pathology, Fujita Health University School of Health SciencesDepartment of Neurosurgery, Fujita Health University School of MedicineDepartment of Neurosurgery, Fujita Health University School of MedicineAbstract Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.https://doi.org/10.1038/s41598-025-85339-xGlioblastomaKarnofsky Performance StatusMGMTRadiotherapyTemozolomideTumor size |
| spellingShingle | Shigeo Ohba Takao Teranishi Kazuyasu Matsumura Masanobu Kumon Daijiro Kojima Eiji Fujiwara Kazutaka Nakao Kiyonori Kuwahara Kazuhiro Murayama Eriel Sandika Pareira Seiji Yamada Masahiro Joko Shunsuke Nakae Jun Muto Yuya Nishiyama Kazuhide Adachi Hikaru Sasaki Masato Abe Mitsuhiro Hasegawa Yuichi Hirose Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy Scientific Reports Glioblastoma Karnofsky Performance Status MGMT Radiotherapy Temozolomide Tumor size |
| title | Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy |
| title_full | Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy |
| title_fullStr | Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy |
| title_full_unstemmed | Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy |
| title_short | Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy |
| title_sort | factors involved in maintaining karnofsky performance status ≥ 50 in glioblastoma idh wildtype patients treated with temozolomide and radiotherapy |
| topic | Glioblastoma Karnofsky Performance Status MGMT Radiotherapy Temozolomide Tumor size |
| url | https://doi.org/10.1038/s41598-025-85339-x |
| work_keys_str_mv | AT shigeoohba factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT takaoteranishi factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT kazuyasumatsumura factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT masanobukumon factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT daijirokojima factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT eijifujiwara factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT kazutakanakao factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT kiyonorikuwahara factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT kazuhiromurayama factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT erielsandikapareira factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT seijiyamada factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT masahirojoko factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT shunsukenakae factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT junmuto factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT yuyanishiyama factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT kazuhideadachi factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT hikarusasaki factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT masatoabe factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT mitsuhirohasegawa factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy AT yuichihirose factorsinvolvedinmaintainingkarnofskyperformancestatus50inglioblastomaidhwildtypepatientstreatedwithtemozolomideandradiotherapy |